ArticleEsophagus : official journal of the Japan Esophageal Society2025
HEYL-mediated activation of LAMA3 influences radiotherapy response in esophageal cancer.
Article in Esophagus : official journal of the Japan Esophageal Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular plasticity of LAMA3 across the disease spectrum: pathogenic mechanisms and clinical translation.Histochemistry and cell biology · 2026Pooled it
- Pan-cancer analysis of Notch pathway-linked gene expression identifies tumour-specific and sex-stratified prognostic associations.Clinical and translational radiation oncology · 2026Article
- Beyond DNA damage: 3D tumor models and the integrin mechanobiology of radioresistance.Journal of experimental & clinical cancer research : CR · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundEsophageal cancer (EC) is a major cause of cancer-related mortality. This study aims to investigate how hairy/enhancer-of-split is related to YRPW motif-like protein (HEYL), which regulates laminin subunit alpha 3 (LAMA3) and its impact on EC radiotherapy via the epithelial-to-mesenchymal transition (EMT) pathway.
methodsDifferentially expressed genes (DEGs) related to radiotherapy sensitivity in EC cells were screened. Radioresistant cells were constructed using X-ray treatment at different doses. LAMA3 expression in radioresistant and parental cells was validated using RT-qPCR and Western blot (WB). γ-H2AX phosphorylation levels were identified to confirm the successful establishment of radioresistant cells. WB and immunofluorescence were performed to detect KI67 and EMT markers (E-cadherin, Slug, and Vimentin). Transwell, wound healing, cell counting kit-8 (CCK-8), and 5-Ethynyl-2'-deoxyuridine (EdU) assays were conducted to assess the response of radioresistant cells to LAMA3 expression alteration. Transcription factors of LAMA3 were predicted and verified. An in vivo model was established to confirm the role that HEYL and LAMA3 played in EMT and radioresistance.
resultsLAMA3 was shown to induce the EMT pathway and reduce radiotherapy efficacy in radiation-resistant OE19R and TE-1R cells. HEYL bound to the LAMA3 promoter, activating its expression. In vitro and in vivo rescue experiments confirmed that HEYL transcriptionally activated LAMA3 to confer resistance to radiotherapy via the EMT pathway in EC.
conclusionIn conclusion, HEYL activates the transcription of LAMA3, which in turn reduces EC radiosensitivity via the EMT pathway.
Indexed as
Identifiers
40833662What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.